sirolimus and Lymphohistiocytosis--Hemophagocytic

sirolimus has been researched along with Lymphohistiocytosis--Hemophagocytic* in 2 studies

Other Studies

2 other study(ies) available for sirolimus and Lymphohistiocytosis--Hemophagocytic

Article	Year
mTORC inhibitor Sirolimus deprograms monocytes in "cytokine storm" in SARS-CoV2 secondary hemophagocytic lymphohistiocytosis- like syndrome. Clinical immunology (Orlando, Fla.), 2020, Volume: 218 Topics: COVID-19; Humans; Lymphohistiocytosis, Hemophagocytic; Monocytes; RNA, Viral; SARS-CoV-2; Sirolimus	2020
Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV-infected perforin-deficient mice. Pediatric blood & cancer, 2011, Dec-15, Volume: 57, Issue:7 Hemophagocytic lymphohistiocytosis (HLH) is an immunodysregulatory disorder for which more effective treatments are needed. The macrolide rapamycin has immunosuppressive properties, making it an attractive candidate for controlling the aberrant T cell activation that occurs in HLH. To investigate its therapeutic potential, we used rapamycin to treat Lymphocytic Choriomeningitis Virus (LCMV)-infected perforin-deficient (Prf1(-/-)) mice according to a well-established model of HLH. At the regimens tested, rapamycin did not improve weight loss, splenomegaly, hemophagocytosis, cytopenias, or proinflammatory cytokine production in LCMV-infected Prf1(-/-) animals. Thus, single agent rapamycin appears ineffective in treating the clinical and laboratory manifestations of LCMV-induced HLH. Topics: Animals; Arenaviridae Infections; Cell Separation; Cytokines; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Immunosuppressive Agents; Lymphocytic choriomeningitis virus; Lymphohistiocytosis, Hemophagocytic; Mice; Mice, Inbred C57BL; Mice, Knockout; Perforin; Sirolimus	2011

Article

Year

mTORC inhibitor Sirolimus deprograms monocytes in "cytokine storm" in SARS-CoV2 secondary hemophagocytic lymphohistiocytosis- like syndrome.

Clinical immunology (Orlando, Fla.), 2020, Volume: 218

Topics: COVID-19; Humans; Lymphohistiocytosis, Hemophagocytic; Monocytes; RNA, Viral; SARS-CoV-2; Sirolimus

2020

Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV-infected perforin-deficient mice.

Pediatric blood & cancer, 2011, Dec-15, Volume: 57, Issue:7

Hemophagocytic lymphohistiocytosis (HLH) is an immunodysregulatory disorder for which more effective treatments are needed. The macrolide rapamycin has immunosuppressive properties, making it an attractive candidate for controlling the aberrant T cell activation that occurs in HLH. To investigate its therapeutic potential, we used rapamycin to treat Lymphocytic Choriomeningitis Virus (LCMV)-infected perforin-deficient (Prf1(-/-)) mice according to a well-established model of HLH. At the regimens tested, rapamycin did not improve weight loss, splenomegaly, hemophagocytosis, cytopenias, or proinflammatory cytokine production in LCMV-infected Prf1(-/-) animals. Thus, single agent rapamycin appears ineffective in treating the clinical and laboratory manifestations of LCMV-induced HLH.

Topics: Animals; Arenaviridae Infections; Cell Separation; Cytokines; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Immunosuppressive Agents; Lymphocytic choriomeningitis virus; Lymphohistiocytosis, Hemophagocytic; Mice; Mice, Inbred C57BL; Mice, Knockout; Perforin; Sirolimus

2011